Characterization of dysfunctional regulatory cells in malignant gliomas
2016
Yale School of Medicine, New Haven, USA
Developing a clear immunological understanding of how immunotherapies work — particularly with respect to the phenotype and function of the cells they target — should enable further improvements of these therapies in the clinic. Immunotherapies targeting the immune checkpoint receptor programmed cell death protein 1 (PD-1) have shown remarkable efficacy in treating cancer. In the present study, the researchers examined functional and molecular features of regulatory T cells positive for PD-1 isolated from patients with glioblastoma multiforme and healthy donors, combining functional assays, RNA sequencing, and cytometry. Overall, patients were shown to display enrichment in dysfunctional regulatory T cells which is in contrast with the current view. The study suggests a need for a more precise single-cell characterization of regulatory T cells to improve immunotherapy design.
PD-1 marks dysfunctional regulatory T cells in malignant gliomas
David A. Hafler
Added on: 09-14-2021
[1] https://insight.jci.org/articles/view/85935#SEC5[2] https://data.jrc.ec.europa.eu/dataset/352f7dfd-05cf-434b-a96a-7e270dc76573
